PYXIS ONCOLOGY

ADCs deliver potent cancer-killing agents directly to tumor cells. Our technology platform is designed to enable us to develop safer and more effective ADCs... We are focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life of patients. We have built a broad portfolio of clinical assets, including novel ADC and mAb product candidates that we are developing as monotherapies and in combination with other therapies... Charting a course to therapeutics for difficult-to-treat cancers.

Primary location: Boston United States